Bayer CV Pact Gives AI-Focused Sensyne Health Its First Big Deal Since 2018 IPO

The UK-based group will help Bayer accelerate clinical development of new treatments for cardiovascular disease using Sensyne Health’s clinical AI technology platform and NHS data.

Digital_Heart
Pact will use AI to speed and improve clinical trials in heart disease • Source: Shutterstock

In its first big commercial pact since listing last year, AI-focused healthcare technology group Sensyne Health PLC has signed an initial two-year collaboration agreement with Bayer AG to hasten the clinical development of new treatments for cardiovascular disease using the UK group’s proprietary technology platform which processes patient data provided by NHS trusts.

The deal is Sensyne Health’s first major drug development agreement since its IPO last August and has potential for expansion,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.